Today: 8 science papers spanning oral STAT6 and nano-PROTAC degraders, PLK4/BChE/STAT3 SAR, and conjugate chemistry, plus 6 business stories led by Lilly's China deal, Novo's Nanexa license, Xofluza pandemic licensing, and two AI-biotech funding rounds.
2026-09-25 · ⚗️BChE (brain-penetrant covalent small-molecule inhibitor) · Journal of Medicinal Chemistry (ACS)
- Researchers used structure-guided design to develop a covalent small-molecule inhibitor of human butyrylcholinesterase (BChE), an enzyme increasingly implicated in Alzheimer's disease progression.
- The lead compound was engineered for blood-brain barrier penetration, a key hurdle for centrally acting cholinesterase inhibitors.
- In vivo testing showed procognitive efficacy, supporting covalent BChE inhibition as a potential treatment approach for Alzheimer's disease.
💡 PointsBChE rising while AChE falls late in disease is finally moving the field past AChE-centric dogma. A covalent warhead in a serine hydrolase family full of close paralogs (AChE, esterases) needs hard selectivity data, not just potency. What actually differentiates this from rivastigmine-class reversible inhibitors is CNS penetration — brain exposure they never solved well.
Structure-Guided Design of a Brain-Penetrant Covalent Inhibitor of Human Butyrylcholinesterase with In Vivo Procognitive Efficacy ↗
2026-09-25 · ⚗️PARP + GPX4 (dual-acting small-molecule inhibitor, ferroptosis inducer) · Journal of Medicinal Chemistry (ACS)
- Medicinal chemists designed single small molecules combining PARP inhibition with GPX4 inhibition, pairing DNA-repair blockade with ferroptosis induction in one compound rather than as a drug combination.
- Structure-activity relationship work identified a new dual-acting chemotype optimized for potency against both targets.
- Lead compounds showed antitumor activity in triple-negative breast cancer models, supporting the dual-mechanism approach as a possible way to broaden PARP inhibitor efficacy.
💡 PointsMost TNBC is BRCA-wild-type, so PARP monotherapy has nowhere to go without synthetic lethality — pairing it with GPX4 inhibition to force ferroptosis is a real way around that, not just an add-on. The tougher ask is holding potency at two unrelated targets in one scaffold without MW/logP creeping past drug-like — if they pulled that off cleanly, it's more interesting than the biology.
Discovery of Dual PARP/GPX4 Inhibitors for the Treatment of Triple-Negative Breast Cancer ↗
2026-09-25 · ⚗️PLK4 (small-molecule kinase inhibitor) · Journal of Medicinal Chemistry (ACS)
- Exelixis researchers optimized an aminopyrazole hit series targeting PLK4, a kinase essential for centriole duplication, culminating in the advanced compound EXEL-1855.
- Structure-guided SAR and selectivity profiling addressed off-target kinase liabilities that had limited earlier aminopyrazole PLK4 inhibitors such as centrinone.
- In preclinical tumor models, EXEL-1855 showed strong antitumor activity, supporting its selection as a development candidate.
💡 PointsSelectivity was always the aminopyrazole scaffold's weak spot — centrinone's off-target kinase hits (PLK1/2/3, Aurora) made it a great chemical probe but a poor drug candidate. Getting EXEL-1855 to "development candidate" with a clean kinome profile is the real milestone here, not the potency number. PLK4's centrosome-duplication mechanism is also refreshingly uncrowded real estate next to the CDK/Aurora pileup.
Lead Optimization of an Aminopyrazole Scaffold to EXEL-1855, a Highly Selective PLK4 Inhibitor with Potent Antitumor Efficacy ↗
2026-09-25 · ⚗️Fluorinated ionizable lipid nanoparticle (nano-PROTAC delivery platform) · Journal of Medicinal Chemistry (ACS)
- Researchers built ionizable lipid nanoparticles with fluorinated lipid tails to encapsulate and deliver a PROTAC degrader payload.
- Tuning the degree of fluorination altered nanoparticle physicochemical properties and redirected intracellular trafficking, promoting more efficient endosomal escape into the cytosol.
- Optimized fluorinated formulations achieved greater cytosolic PROTAC release and stronger target-protein degradation than non-fluorinated lipid controls.
💡 PointsMost LNP-delivered PROTAC payload never escapes the endosome — it gets trapped and degraded lysosomally, so tuning fluorine content on the lipid tail to boost cytosolic release is a smart lever, borrowed straight from siRNA-LNP playbooks. If this scaffold generalizes beyond whichever degrader they tested, it could rescue plenty of otherwise-undruggable bifunctional PROTACs too big or polar for oral dosing.
Fluorination-Tuned Ionizable Lipids Regulate Nano-PROTAC Trafficking for Enhanced Targeted Protein Degradation ↗
2026-09-25 · ⚗️Tn antigen (Tyr-GalNAc, bacteriophage Qβ VLP conjugate vaccine) · Journal of the American Chemical Society (ACS)
- Chemists built fluorinated Tn-antigen mimics using a tyrosine-linked GalNAc (Tyr-GalNAc) instead of the natural serine/threonine attachment, then conjugated them to bacteriophage Qβ virus-like particles.
- Qβ is a multivalent carrier platform known for driving strong antibody responses to small carbohydrate tumor antigens.
- The fluorinated Tyr-GalNAc-Qβ conjugates showed potent antitumor activity in preclinical models, adding to evidence that targeted fluorination can boost carbohydrate-antigen vaccine immunogenicity.
💡 PointsTn's Achilles' heel has always been the native GalNAc-α-O-Ser/Thr linkage: glycosidase-labile and a weak, self-like hapten that struggles to break B-cell tolerance. Rerouting to a Tyr-aryl glycoside dodges the enzymes evolved for O-Ser/Thr GalNAc, and fluorination looks like classic conformational/electronic tuning to sharpen epitope recognition. Neither move touches the target — it's synthetic hapten engineering, with Qβ's ~180-copy multivalent display doing the real work of forcing an antibody response.
Synthesis of Fluorinated Tyr-GalNAc Antigens and Potent Antitumor Activity of Their Bacteriophage Qβ Conjugates ↗
2026-09-25 · ⚗️STAT6 (PROTAC degrader) · Journal of Medicinal Chemistry (ACS)
- A new PROTAC degrader targets STAT6, the transcription factor that carries IL-4/IL-13 signals driving Th2-type allergic inflammation.
- Instead of inhibiting STAT6, the molecule links a STAT6-binding fragment to a degradation handle for potency and selectivity over related STAT proteins.
- It reportedly showed oral efficacy in preclinical models, pointing to a pill-based alternative to injectable biologics for atopic dermatitis.
💡 PointsOral bioavailability is the harder win here than target choice — PROTACs routinely blow past Lipinski/bRo5 limits (MW, PSA), so a gut-stable, orally efficacious degrader is the rarer synthetic feat. If STAT1/3/5 selectivity holds up in vivo, this leapfrogs injectable dupilumab and pressures other oral STAT6 degrader programs already in the clinic.
Discovery of a Potent, Selective, and Orally Efficacious STAT6 PROTAC for the Treatment of Atopic Dermatitis ↗
2026-09-23 · ⚗️AOC (antibody-siRNA conjugate chemistry) · bioRxiv
- A new bioRxiv preprint investigates how the chemical architecture of antibody-oligonucleotide conjugates (AOCs) affects their performance as siRNA delivery vehicles.
- The work examines design variables such as linker composition, conjugation site on the antibody, and siRNA chemical modification pattern.
- Findings aim to clarify which structural choices most influence knockdown potency and delivery efficiency, informing rational AOC design.
💡 PointsWhether AOC chemists can transplant ADC lessons on conjugation-site control and linker stability wholesale — or oligo payloads demand their own rules — matters more than the siRNA payload itself. Locking down DAR and site-specificity is what turns AOCs into the extrahepatic answer GalNAc conjugates can't be, which is exactly why Alnylam, Avidity, and everyone else is racing to nail this chemistry first.
Enhancing the efficacy of siRNA Antibody Oligonucleotide Conjugates (AOCs) through chemical design ↗
2026-09-25 · 🏢FDA approval · STAT News · Eli Lilly
- The FDA approved Eli Lilly's Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin for adults with type 2 diabetes, offering an alternative to daily long-acting injections.
- Approval drew on the QWINT trial program in over 3,400 patients, where Onswik's blood-sugar control was comparable to daily insulin glargine or degludec.
- Onswik is the second once-weekly basal insulin cleared in the US, after Novo Nordisk's Awiqli (icodec); Lilly expects US availability within months.
💡 PointsSecond mover, not first: Onswik only claims non-inferiority to daily glargine/degludec in QWINT, so Lilly can't out-argue Awiqli on efficacy — it has to out-sell it, bundling weekly insulin into the same reps and formulary contracts as Trulicity/Mounjaro. Insulin, the industry's most commoditized category, just became the GLP-1 giants' next cross-sell battleground.
Lilly wins approval for once-weekly insulin shot ↗
2026-09-25 · 🏢licensing deal / drug-delivery partnership · Endpoints News · Novo Nordisk / Nanexa
- Novo Nordisk signed a global licensing deal with Swedish biotech Nanexa for its ALD-based PharmaShell platform, which coats drug particles to control release.
- Covers up to five programs in obesity, diabetes and cardiometabolic disease, aiming for monthly/quarterly dosing versus more frequent injections.
- Worth up to €1.165B, with ~€615M upfront/milestones plus royalties; Nanexa shares more than doubled.
💡 PointsNovo again chooses a capital-light platform bet over a big asset buy: licensing unproven ALD nanocoating across five programs to chase Lilly's once-monthly ambitions, since monthly dosing is what keeps patients on therapy once oral GLP-1s and biosimilars start undercutting Wegovy on convenience. Tellingly, ~€615M upfront/milestones against a €1.165B ceiling means Nanexa, not Novo, fronts most of the technical risk until PharmaShell proves out in humans.
Novo does another small deal, this time with drug delivery biotech Nanexa ↗
2026-09-25 · 🏢licensing deal / pandemic preparedness · STAT News · Roche; Medicines Patent Pool
- The Medicines Patent Pool signed sub-licensing deals with 11 generic manufacturers to produce Roche's flu antiviral Xofluza (baloxavir marboxil).
- The agreements, building on MPP's broader license with Roche, cover supply to roughly 129 low- and middle-income countries and include technical support for regulatory approval.
- They also carry pandemic-specific provisions meant to ease supply, territory and royalty constraints if a global flu outbreak occurs.
💡 PointsRoche is front-running compulsory-licensing pressure here, not waiting for a pandemic to force its hand the way COVID access fights forced others — cheap reputational insurance bought years early. But 11 sub-licensees on paper isn't surge capacity: without tech-transfer and validation runs now, that capacity stays theoretical until an outbreak tests it. Still, MPP's Xofluza network beats what Gilead ever built for oseltamivir — a real bar-raise on pandemic-prep licensing.
Licensing deals on generic versions of Roche flu drug aimed at preparing for pandemic ↗
2026-09-24 · 🏢discovery collaboration / licensing deal · Endpoints News · Eli Lilly / InnoCare Pharma
- Eli Lilly signed a discovery-stage collaboration and licensing deal with Beijing-based InnoCare Pharma worth up to $3.35 billion.
- Terms include up to $100 million upfront, up to $3.25 billion in milestones, and royalties, as InnoCare hunts compounds against up to five undisclosed targets.
- It marks Lilly's fourth China-biotech deal since early 2025, after Insilico Medicine, Innovent Biologics and Haisco.
💡 PointsFourth China-sourced discovery deal for Lilly since early 2025 — this is deliberate strategy, not opportunism: outsourcing early-target risk to lower-cost Chinese biotech engines. The $100M upfront against $3.35B total (~3%) is a cheap option on unproven targets, not a derisked buy. China's shifting from manufacturing base to discovery pipeline for Big Pharma.
In another China pact, Lilly makes a deal with InnoCare worth up to $3.35B ↗
2026-09-23 · 🏢venture funding round · Endpoints News · Basecamp Research
- Basecamp Research, a London-based AI drug design startup, closed an oversubscribed $140M Series C led by S32 at an ~$800M valuation, with Nvidia, Anthropic's Anthology Fund and other investors participating.
- Funds will train next-generation EDEN foundation models built on the firm's proprietary environmental and biodiversity genomic dataset.
- The financing advances a pipeline of AI-designed therapeutics, starting with in vivo cell therapies, toward clinical development.
💡 PointsBasecamp isn't training on the same public protein databases every AI-discovery rival uses — its moat is proprietary environmental and biodiversity genomics, genuinely hard to replicate, worth more than the $800M valuation headline. Nvidia and Anthropic both backing one biology-foundation-model shop reads as infrastructure players staking platform claims on bio FMs, and opening the pipeline with in vivo cell therapy instead of small molecules is a far riskier first bet to prove the thesis in clinic.
AI startup Basecamp Research raises $140M Series C, shares pipeline ↗
2026-09-23 · 🏢venture funding round · Fierce Biotech · Enveda Biosciences
- Enveda Biosciences closed a $311 million Series E led by Catalio Capital Management, joined by several new and existing investors.
- The round roughly doubles Enveda's valuation to about $2 billion and lifts total funding raised past $845 million.
- Enveda uses AI to mine natural-product chemistry for drug candidates and will use proceeds to push its clinical pipeline, including atopic dermatitis and metabolic disease programs, into later-stage trials.
💡 PointsA $311M Series E in this financing climate signals investors underwriting actual clinical data on two candidates, not just an AI-platform pitch. Enveda's moat is mining natural-product chemical space that synthetic-library-focused rivals ignored; the harder test is atopic dermatitis, where biologics like Dupixent already dominate and a small molecule needs a clear differentiation story to matter.
Enveda reaps $311M round to feed its ambition to become a 'household name' ↗